



Surgical clinical trials with non-inferiority design: a cross-sectional bibliometric analysis

Chi Shu^{1,2,3}, Bin Huang¹, Ding Yuan¹, Yi Yang¹, Xiaojiong Du¹, Yazhou He⁴, Xin Chen⁴, Jichun Zhao¹

¹Department of Vascular Surgery, West China Hospital, Sichuan University, Chengdu, China; ²West China School of Medicine, Sichuan University, Chengdu, China; ³Department of Vascular Surgery, Toronto General Hospital, Toronto, ON, Canada; ⁴Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China

Contributions: (I) Conception and design: X Chen, C Shu, B Huang; (II) Administrative support: X Chen, Y Yang; (III) Provision of study materials or patients: X Chen, Y Yang; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Jichun Zhao. Department of Vascular Surgery, West China Hospital, Sichuan University, 37 Guo Xue Alley, Chengdu 610041, China. Email: zhaorc3@163.com; Xin Chen. Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University, 16 Ren Min South Street, Chengdu 610041, China. Email: liangchaokaiji@foxmail.com.

Background: Wide-spread concerns have been raised about possible bias in published surgical non-inferiority trials. Therefore, we performed a comprehensive bibliometric analysis to identify the existence of bias, and provided recommendations for future non-inferiority trials.

Methods: Databases including MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were systematically searched (last update on 27 April 2020) to include published phase II and phase III non-inferiority surgical trials. We collected general information and parameters associated with trial design. The association between extracted factors and establishment of non-inferiority was then analyzed.

Results: A total of 347 trials were included in this study. Only 13 (3.7%) trials reported the pre-specified non-inferiority margin in registration, and 99 (28.5%) trials justified margin selection in ultimate trial publications. A significant association was found between industry funding and increased odds of achieving non-inferiority [odds ratio (OR): 1.17, 95% confidence interval (CI): 1.06 to 1.30, P=0.001]. Moreover, trials which had been presented in conferences were less likely to claim non-inferiority (OR: 0.83, 95% CI: 0.69 to 0.99, P=0.035).

Conclusions: Our study was the first quantitative analysis revealing the presence of biases in findings of existing surgical non-inferiority trials, which could possibly mislead surgeons' clinical decision making. We suggest improving reporting of detailed study design especially funding sources as well as margin justification for future trials. We also encourage conference presentation of ongoing trials prior to the ultimate publication.

Keywords: Non-inferiority; design; bias; surgical trial; bibliometric analysis

Submitted May 12, 2021. Accepted for publication Aug 11, 2021.

doi: 10.21037/atm-21-2626

View this article at: <https://dx.doi.org/10.21037/atm-21-2626>

Introduction

Non-inferiority design has been deployed in a growing number of surgical clinical trials. It is the optimal choice for investigating new surgical procedures which may not present significant clinical superiority but offers certain

advantages such as increased cost-efficiency, ease of operation, and reduced invasiveness (1). To date, a few surgical novel techniques, such as the robot-assisted and laparoscopic procedures (2,3), have been recommended by official guidelines based on the findings of non-inferiority trials.

Concluding non-inferiority is based on comparison between confidence intervals of treatment effects and pre-defined and clinically acceptable margins, known as non-inferiority margins. One of the most challenging points in non-inferiority design is margin justification since it should balance both clinical and statistical perceptions (4). Theoretically, the probability of establishing non-inferiority should be independent from pre-specified parameters except for the type II error (β) or statistical power under the alternative hypothesis. However, there have been widespread concerns regarding the validity of established non-inferiority, especially on account of the arbitrary definition of non-inferiority (5), where biases could stem from (6,7). An earlier systematic review found that even in high-quality journals, non-inferiority design of clinical trials was reported inconsistently and did not follow official recommendations (8). Biased findings of non-inferiority, if approved by guidelines, could potentially mislead surgeons in clinical decision-making and eventually result in patients receiving inferior surgical treatments. However, quantitative evidence is still lacking, leaving this issue unsolved.

To determine the existence of bias, we explored the external factors that influence the establishment of non-inferiority by systematically surveying and analyzing the characteristics of published surgical clinical trials.

We present the following article in accordance with the PRISMA reporting checklist (available at <https://dx.doi.org/10.21037/atm-21-2626>).

Methods

Search strategy and trial selection

Databases including MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were systematically searched (last update on 27 April 2020, detailed strategy presented in [Table S1](#)) with a limitation to publications in the English language. The search was restricted to clinical trials in MEDLINE and Embase. The registry identifier and references of included studies were also cross-checked for additional trials.

All retrieved records were screened by two reviewers (C.S. and B.H.). We included non-inferiority trials that investigated surgical procedures of treatment purposes in at least one treatment arm based on the recommendations from the PubMed queries (9), and excluded trials regarding the diagnostic, cosmetic, and obstetric procedures (10). The inclusion criteria were as follows: completed or ongoing

trials with published results; trials aiming to prove non-inferiority of a new treatment (procedure, technique, material, and so on) to a conventional one, and at least one treatment was surgical related; trials reporting whether the non-inferiority was established. For multiple publications with the same registry identifier, only the one reporting the ultimate findings of the primary outcome was included. Subgroup and post hoc analyses were not eligible. Any discrepancies were solved by discussion with a senior surgeon (J.Z.) and an epidemiologist (D.Y.).

Data extraction

A standard data extraction of included studies was performed by one author (C.S.) with an Excel form and checked by a second author (X.C.). Discrepancies were reviewed and discussed to reach agreement. Essential characteristics of the eligible studies were abstracted by two reviewers (C.S. and X.C.) independently, including first author, publication year, journal name and impact factor in 2019, single or multi-center trial, trial status (completed, interim, or terminated), trial registry number, surgical specialty (e.g., cardiovascular, digestive, urogenital, orthopedic, and so on), follow-up time (months), primary outcome (e.g., event free survival, surgical success, late luminal loss, etc.), funding source (industry or non-industry), conference presentation, and declaration of competing interests.

We also collected methodologic parameters associated with study design including outcome event rate, 1-sided type I error (α), type II error (β), non-inferiority margin reported as both absolute differences such as rate difference and relative effect sizes such as hazard ratios (HR), odds ratios (OR), and risk ratios (RR), justifications of margin selection and estimated sample size. We evaluated the establishment of non-inferiority by examining whether the upper bound of estimated confidence interval (CI) exceeded the pre-specified non-inferiority margin.

Statistical analysis

We performed descriptive analysis for the extracted general characteristics. In particular, categorical variables were expressed as frequencies, while median and interquartile range (IQR) were used for continuous variables. We performed Pearson's Chi-square (χ^2) tests and Mann-Whitney U tests to compare the differences of distribution patterns of categorical and continuous characteristics, respectively, between trials with and without establishing

non-inferiority. A 2-sided P value <0.05 was considered as an indicator for significant association between a certain factor and establishment of non-inferiority. Since the probability of establishing non-inferiority should theoretically only be dependent on the type II error (β) under the alternative hypothesis, any other external factors associated with establishment of non-inferiority would imply potential bias. Notably, to model the effect of non-inferiority margin on reported outcome of non-inferiority, we first transformed margins expressed as rate difference to RRs based on the baseline outcome event rate. With regard to studies using continuous effect estimates such as mean differences as the primary outcome, we standardized the effect estimates with the reported standard deviations (SD), and then transformed the continuous estimates to ORs following the Hasselblad and Hedges' method (11,12). A previous study had shown that HRs, ORs, and RRs can be good numerical approximations of one another (13). Therefore, we took the coefficient scale of log-transformed relative effects (HRs, RRs, and ORs) and investigated their association with ultimate establishment of non-inferiority.

All statistical analyses were performed using R (version 4.0.2; <https://www.R-project.org/>).

Results

Selection of studies

A total of 3,312 records were retrieved from the aforementioned three databases. After reviewing titles and abstracts, 746 records were identified for in-depth full-text review. Through cross-checking the trial registry identifier and reference of eligible studies, we enrolled 3 additional studies. At last, 347 non-inferiority surgical clinical trials were included in our study. The flow chart of study selection is presented in *Figure 1*.

General trial characteristics

Basic characteristics of the 347 eligible trials are shown in *Table 1*, with detailed information available in *Table S2*. Among all the trials, 277 (79.8%) claimed non-inferiority in conclusion. As for methodologic parameters, not much diversity was observed in terms of type I (median 0.05, IQR 0.025–0.05) and type II error (median 0.20, IQR 0.10–0.20); the median sample size was 261 with IQR between 136 and 800; the majority of non-inferiority margins in HR were less than 2 and with a median number of 1.46 (IQR

1.23–2.00). Only 99 (28.5%) trials reported justification for the margin and 58 (58.6%) of them were based on previous trials, while 19 (19.2%) used effect retention method and 16 (16.2%) relied on expert consensus. A total of 204 (58.8%) trials reported method for sample size calculation; of them, 187 (91.7%) were based on previous trials, and only 15 (7.4%) followed instructions from methodologic studies.

Quantitative analysis

As presented in *Table 2*, the essential characteristics were compared between trials with or without establishment of non-inferiority. Among all surgical specialties, cardiovascular related interventions were performed in 157 (56.7%) trials that claimed non-inferiority and 29 (41.4%) trials that failed, which were the highest in both groups. The distribution of surgical specialties was not significantly associated with the establishment of non-inferiority ($P=0.09$). In trials that achieved non-inferiority, a lower percentage of published protocols (15.9% *vs.* 22.9%) and lower journal impact factor (6.38 *vs.* 8.43) were observed, although no significant difference was detected. A significant association was found between industry funding and increased odds of achieving non-inferiority (OR: 1.17, 95% CI: 1.06 to 1.30, $P=0.001$). In addition, trials that presented their findings in conferences were significantly less likely to establish non-inferiority (OR: 0.83, 95% CI: 0.69 to 0.99, $P=0.035$). Regarding parameters associated with trial design, only 13 (3.7%) trials reported the pre-specified margin in registration, and 99 (28.5%) trials justified their selection of non-inferiority margin. No significant associations were identified between the established non-inferiority and other parameters including type I error, type II error, non-inferiority margin, and sample size.

Discussion

Multiple studies have investigated the design, conduct, and interpretation of surgical non-inferiority trials and highlighted the deficiencies such as arbitrary selection of margin and poor quality of reporting (14,15). These studies, however, have only focused on a subspecialty, such as surgical oncology, and were therefore limited by small number of included trials. Therefore, we performed a systematic bibliometric analysis which summarized 347 previously published non-inferiority phase II and III surgical trials.

To our best knowledge, this is the first effort that




Figure 1 Flow diagram of study selection process.

quantitatively assessed factors associated with findings of published non-inferiority trials in surgery. We identified industry funding and conference presentation as potential sources of bias in surgical non-inferiority trials. We detected significant industry sponsorship bias which led to the excess establishment of non-inferiority in existing surgical clinical trials, resonating with a previous systematic review which included trials from all disciplines and found that industry-funded trials were more likely to use non-inferiority designs and report “favorable” results (16). To improve transparent reporting, funding sources should

be clearly reported both in the trial registration record and the ultimate publication. If an industry-funded trial chooses a product from competing companies as the control arm, a specified statement should be added as part of the competing of interests. We also found that underreporting of trial design and trial results prior to the ultimate publication of trial findings was associated with higher probability of concluding non-inferiority. Based on our findings, conference presentations should be encouraged as it might help preventing possible post-hoc distortion to the original study design. In addition to these biases,

Table 1 Summary of essential characteristics of the 347 included non-inferiority trials

Characteristics	Number (%)
Trial status	
Full report	347
Completed	331 (95.4)
Interim	2 (0.6)
Terminated	14 (4.0)
Publication year	
2016–2020	175 (50.4)
2011–2015	131 (37.8)
2006–2010	37 (10.7)
2003–2005	4 (1.1)
Country	
Europe	159 (45.8)
Asia	93 (26.8)
North America	87 (25.1)
Others	8 (2.3)
Multi-center trials	
Yes	297 (85.6)
No	50 (14.4)
Trial registered	
Yes	287 (82.7)
No	60 (17.3)
Registry institution	
Clinical trial.gov	237 (82.6)
UMIN	12 (4.2)
NTR	12 (4.2)
ISRCTN	10 (3.5)
ChiCTR	5 (1.7)
Others	11 (3.8)
Type of comparison	
Surgery vs. surgery	325 (93.7)
Surgery vs. medication	22 (6.3)
Comparison between different procedures (surgery vs. surgery)	
Stent vs. stent	119 (36.6)
Open surgery vs. open surgery	102 (31.4)
Intervention vs. intervention	71 (21.8)
Open surgery vs. intervention	33 (10.2)

Table 1 (continued)**Table 1** (continued)

Characteristics	Number (%)
Primary endpoint	
Survival	
Event free survival	120 (34.6)
Overall survival	21 (6.1)
Recurrence free survival	14 (4.0)
Disease free survival	7 (2.0)
Surgical success	
Success rate	86 (24.8)
Continuous	
Late luminal loss	51 (14.7)
Score or index	26 (7.5)
Others	22 (6.3)

UMIN, University Hospital Medical Information Network; NTR, Netherlands Trial Registry; ISRCTN, International Standard Randomized Controlled Trial Number Register; ChiCTR, Chinese Clinical Trial Register.

it is worth noting that our study focuses on randomized controlled trials, which may have limited generalizability. Non-inferiority achieved by existing surgical trials should be further validated in the real-world settings due to potentially diverse population (17).

In our study, we found that methodological details of non-inferiority design were severely underreported in current surgical trials. For example, among the 347 eligible trials, only 99 (28.5%) justified their selection of non-inferiority margin, which is comparable to a prior study including trials from all disciplines (6). Poorly justified margin specification could lead to excess achievement of non-inferiority; although in our study, the transformed margin was not associated with establishment of non-inferiority ($P=0.81$). We thereby call for compulsory reporting of non-inferiority margin and margin justification details in trial registry such as Clinicaltrials.gov and published articles. Any protocol amendment should be documented in detail with caution.

Although no association was observed between surgical specialty and establishment of non-inferiority in our study, potential bias could have been generated, which merits further investigation. In particular, among all included trials of our study, 186 (53.6%) trials investigated cardiovascular and peripheral vascular surgeries, and 57 (16%) trials investigated general surgeries. A prior cross-sectional

Table 2 Characteristics of 347 trials with or without establishment of non-inferiority

Characteristics	Trials with non-inferiority established*		P values**
	Yes (N=277)	No (N=70)	
Surgical specialty, n (%)			
Cardiovascular	157 (56.7)	29 (41.4)	0.09
Digestive	40 (14.4)	17 (24.3)	
Urogenital	36 (13.0)	15 (21.4)	
Orthopedic	26 (9.4)	3 (4.3)	
Other	18 (6.5)	6 (8.6)	
Journal impact factor	6.38 (3.19–23.05)	8.43 (4.56–28.43)	0.19
Follow-up time (months)	12.00 (9.00–12.00)	12.00 (6.75–24.00)	0.67
Protocol published, n (%)			
Yes	44 (15.9)	16 (22.9)	0.15
No	233 (84.1)	54 (77.1)	
Funding type, n (%)			
Non-industry	68 (29.8)	31 (52.5)	0.001
Industry	160 (70.2)	28 (47.5)	
Conference presentation, n (%)			
Yes	13 (4.7)	8 (11.4)	0.03
No	264 (95.3)	62 (88.6)	
Conflicts of interest, n (%)			
Yes	177 (63.9)	40 (57.1)	0.30
No	100 (36.1)	30 (42.9)	
Parameters associated with study design			
Pre-specified margin in registration, n (%)			
Yes	11 (4.0)	2 (2.9)	0.66
No	266 (96.0)	68 (97.1)	
Type I error	0.05 (0.025–0.05)	0.05 (0.044–0.05)	0.10
Type II error	0.2 (0.10–0.20)	0.2 (0.11–0.20)	0.24
Non-inferiority margin	1.46 (1.23–2.02)	1.42 (1.23–1.88)	0.81
Margin justification, n (%)			
Yes	83 (30.0)	16 (22.9)	0.24
No	194 (70.0)	54 (77.1)	
Sample size	260 [140–820]	289 [118–737]	0.82

*, medians and quartiles were used for continuous variables; **, P values for chi-square tests except for follow-up time where a Mann-Whitney U test was used.

survey focusing on all types of surgical trials reported that general surgery accounted for the largest proportion (34.5%) of all published surgical trials (10). Our findings indicated that non-inferiority design might be more commonly adopted in trials of cardiovascular surgeries. In our study, 119 (34.3%) trials focused on comparisons across different types of coronary stents. Whether these trials adopted non-inferiority design in order to chase higher probability of achieving favorable outcomes, and what role funders played in selecting this type of study design remain unclear, and therefore are yet to be explored in-depth by future research.

The main limitation of our study is that we only enrolled published trials which were indexed in databases such as MEDLINE, Embase, and Cochrane Central which led to omission of unpublished data.

In summary, we systematically analyzed previously published non-inferiority trials in surgery and identified potential biases in such type of trials. Based on our findings, future trials should continue to improve transparent reporting of potential conflicts of interests especially the funding sources. In addition, trials are encouraged to be presented in conferences to increase visibility and to some extent prevent post-hoc manipulation of the study design. Last but not the least, trials should be registered with full details of study design in registries such as Clinicaltrials.gov, or publish these details in the protocol.

Acknowledgments

We thank Dr. Xia Shen for providing consultations to the statistical analysis, and as well as Dr. Thomas Forbes for the clinical guidance.

Funding: None.

Footnote

Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at <https://dx.doi.org/10.21037/atm-21-2626>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/atm-21-2626>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Mulla SM, Scott IA, Jackevicius CA, et al. How to use a noninferiority trial: users' guides to the medical literature. *JAMA* 2012;308:2605-11.
2. Merseburger AS, Herrmann TR, Shariat SF, et al. EAU guidelines on robotic and single-site surgery in urology. *Eur Urol* 2013;64:277-91.
3. Zerey M, Hawver LM, Awad Z, et al. SAGES evidence-based guidelines for the laparoscopic resection of curable colon and rectal cancer. *Surg Endosc* 2013;27:1-10.
4. Middleton LJ. Falling in the margin: Randomised controlled trials with a non-inferiority design. *BJOG* 2021. [Epub ahead of print]. doi: 10.1111/1471-0528.16702.
5. Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. *Lancet Oncol* 2015;16:364-6.
6. Gopal AD, Desai NR, Tse T, et al. Reporting of noninferiority trials in ClinicalTrials.gov and corresponding publications. *JAMA* 2015;313:1163-5.
7. Mauri L, D'Agostino RB Sr. Challenges in the Design and Interpretation of Noninferiority Trials. *N Engl J Med* 2017;377:1357-67.
8. Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. *BMJ Open* 2016;6:e012594.
9. Surgical Procedures, Operative. National Center for Biotechnology Information. Available online: <https://www.ncbi.nlm.nih.gov/mesh/68013514>. (Accessed in April 2020). 2020.
10. Yu J, Chen W, Chen S, et al. Design, Conduct, and Analysis of Surgical Randomized Controlled Trials: A Cross-sectional Survey. *Ann Surg* 2019;270:1065-9.
11. da Costa BR, Rutjes AW, Johnston BC, et al. Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study. *Int J Epidemiol* 2012;41:1445-59.

12. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. *Psychol Bull* 1995;117:167-78.
13. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. *J Clin Epidemiol* 2002;55:893-9.
14. Parsyan A, Marini W, Fazelzad R, et al. Current Issues in Conduct and Reporting of Noninferiority Randomized Controlled Trials in Surgical Management of Cancer Patients. *Ann Surg Oncol* 2021;28:39-47.
15. Blencowe NS, Chana P, Whistance RN, et al. Outcome reporting in neoadjuvant surgical trials: a systematic review of the literature and proposals for new standards. *J Natl Cancer Inst* 2014;106:dju217.
16. Flacco ME, Manzoli L, Boccia S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. *J Clin Epidemiol* 2015;68:811-20.
17. Zhou YL, Zhang YG, Zhang R, et al. Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital. *Chin Med J (Engl)* 2021;134:1317-23.

Cite this article as: Shu C, Huang B, Yuan D, Yang Y, Du X, He Y, Chen X, Zhao J. Surgical clinical trials with non-inferiority design: a cross-sectional bibliometric analysis. *Ann Transl Med* 2021;9(16):1302. doi: 10.21037/atm-21-2626

Table S1 Search strategies for MEDLINE, Embase, and Cochrane Central Register of Controlled Trials

Database: MEDLINE (Limited to human studies)

Surgical Procedures, Operative.mp. or exp Surgical Procedures, Operative/or Specialties, Surgical.mp. or exp Specialties, Surgical/ or surgery.mp. or Minimally Invasive Surgical Procedures.mp. or exp Minimally Invasive Surgical Procedures/or (Surgery or Surgeries or Surgeries or Surgical or Operative or Perioperative or Intraoperative or Postoperative or Intervention* or Invasive).af.

AND

Noninferiority.mp. or Non inferiority.mp. or (Non-inferiority or Noninferiority or Non-inferior or Noninferior).af.

AND

Clinical trial.mp. or exp Clinical Trial/or Randomized Controlled Trial.mp. or exp Randomized Controlled Trial/or Trial.mp. or Trial.af.

Database: Embase (Limited to human studies)

exp Surgery/or Surgery.mp. or Surgical technique.mp. or exp Surgical technique/or Surgical technology.mp. or exp Surgical technology/ or Surgical.mp. or Minimally invasive surgery.mp. or exp Minimally invasive surgery/or (Surgery or Surgeries or Surgeries or Surgical or Operative or Perioperative or Intraoperative or Postoperative or Intervention* or Invasive).af.

AND

Noninferiority.mp. or Non inferiority.mp. or (Non-inferiority or Noninferiority or Non-inferior or Noninferior).af.

AND

Clinical trial.mp. or exp Clinical trial/or Non-inferiority trial.mp. or exp Non-inferiority trial/or Randomized controlled trial.mp. or exp Randomized controlled trial/or Trial.mp. or Trial.af.

Database: Cochrane Central Register of Controlled Trials (Words variations were searched)

("Surgery"):ti,ab,kw OR ("noninferiority"):ti,ab,kw

References

1. Schiele F, Meneveau N, Gilard M, et al. Intravascular ultrasound-guided balloon angioplasty compared with stent: Immediate and 6-month results of the multicenter, randomized Balloon Equivalent to Stent study (BEST). *Circulation* 2003;107:545-51.
2. Nelson H, Sargent DJ, Wieand HS, et al. A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer. *New England Journal of Medicine* 2004;350:2050-9+114.
3. Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *New England Journal of Medicine* 2004;351:1493-501+586.
4. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. *New England Journal of Medicine* 2005;353:663-70.
5. Hacke W. 30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. *Lancet* 2006;368:1239-47.
6. Kitchener HC, Dunn G, Lawton V, et al. Laparoscopic versus open colposuspension--results of a prospective randomised controlled trial. *BJOG: An International Journal of Obstetrics & Gynaecology* 2006;113:1007-13.
7. Mas JL, Chatellier G, Beyssen B, et al. Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. *New England Journal of Medicine* 2006;355:1660-71.
8. Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. *European Heart Journal* 2006;27:260-6.
9. Mehilli J, Kastrati A, Wessely R, et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. *Circulation* 2006;113:273-9.
10. Wright D, Gobin JP, Bradbury AW, et al. Varisolve polydocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. *Phlebology* 2006;21:180-90.
11. Turco MA, Ormiston JA, Popma JJ, et al. Polymer-Based, Paclitaxel-Eluting TAXUS Liberte Stent in De Novo Lesions. The Pivotal TAXUS ATLAS Trial. *Journal of the American College of Cardiology* 2007;49:1676-83.
12. Barber MD, Kleeman S, Karram MM, et al. Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence: A randomized controlled trial. *Obstetrics and Gynecology* 2008;111:611-21.
13. Chevalier B, Di Mario C, Neumann FJ, et al. A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries. The ZoMaxx I Trial. *JACC: Cardiovascular Interventions* 2008;1:524-32.
14. Krucoff MW, Kereiakes DJ, Petersen JL, et al. A Novel Bioresorbable Polymer Paclitaxel-Eluting Stent for the Treatment of Single and Multivessel Coronary Disease. Primary Results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II Study. *Journal of the American College of Cardiology* 2008;51:1543-52.
15. Ormiston JA, Mahmud E, Turco MA, et al. Direct Stenting With the TAXUS Liberte Drug-Eluting Stent. Results From the TAXUS ATLAS DIRECT STENT Study. *JACC: Cardiovascular Interventions* 2008;1:150-60.
16. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial. *JAMA - Journal of the American Medical Association* 2008;299:1903-13.
17. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. *Journal of the European Academy of Dermatology and Venereology* 2008;22:1302-11.
18. Turco MA, Ormiston JA, Popma JJ, et al. Reduced Risk of Restenosis in Small Vessels and Reduced Risk of Myocardial Infarction in Long Lesions With the New Thin-Strut TAXUS Liberte Stent. 1-Year Results From the TAXUS ATLAS Program. *JACC: Cardiovascular Interventions* 2008;1:699-709.
19. Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. *The Lancet* 2008;372:1163-73.
20. Bonjer. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. *The Lancet Oncology* 2009;10:44-52.
21. Byrne RA, Kastrati A, Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with

- different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. *European Heart Journal* 2009;30:2441-9.
22. Chevalier B, Silber S, Park SJ, et al. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2. *Circulation: Cardiovascular Interventions* 2009;2:188-95.
 23. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *The Lancet* 2009;374:534-42.
 24. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine Journal* 2009;9:275-86.
 25. Puskas JD, Halkos ME, Balkhy H, et al. Evaluation of the PAS-Port Proximal Anastomosis System in coronary artery bypass surgery (the EPIC trial). *Journal of Thoracic and Cardiovascular Surgery* 2009;138:125-32.
 26. Saltzman CL, Mann RA, Ahrens JE, et al. Prospective controlled trial of STAR total ankle replacement versus ankle fusion: Initial results. *Foot and Ankle International* 2009;30:579-96.
 27. Serruvs PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *New England Journal of Medicine* 2009;360:961-72.
 28. Thiele H, Neumann-Schniedewind P, Jacobs S, et al. Randomized Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery Versus Sirolimus-Eluting Stenting in Isolated Proximal Left Anterior Descending Coronary Artery Stenosis. *Journal of the American College of Cardiology* 2009;53:2324-31.
 29. Verheye S, Agostoni P, Dawkins KD, et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent System in Patients with De Novo Lesions of the Native Coronary Arteries) Trial. *JACC: Cardiovascular Interventions* 2009;2:205-14.
 30. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. *Heart* 2010;96:1291-6.
 31. Darai E, Dubernard G, Coutant C, et al. Randomized trial of laparoscopically assisted versus open colorectal resection for endometriosis: morbidity, symptoms, quality of life, and fertility. *Annals of Surgery* 2010;251:1018-23.
 32. Kapur A, Hall RJ, Malik IS, et al. Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. 1-Year Results of the CARDia (Coronary Artery Revascularization in Diabetes) Trial. *Journal of the American College of Cardiology* 2010;55:432-40.
 33. Kereiakes DJ, Cannon LA, Feldman RL, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. *J Am Coll Cardiol* 2010;56:264-71.
 34. Leon MB, Mauri L, Popma JJ, et al. A Randomized Comparison of the Endeavor Zotarolimus-Eluting Stent Versus the TAXUS Paclitaxel-Eluting Stent in De Novo Native Coronary Lesions. 12-Month Outcomes From the ENDEAVOR IV Trial. *Journal of the American College of Cardiology* 2010;55:543-54.
 35. Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. *European Urology* 2010;57:196-201.
 36. Ormiston JA, Abizaid A, Spertus J, et al. Six-month results of the NEVO res-elution I (NEVO RES-I) Trial : A randomized, multicenter comparison of the nevo sirolimus-eluting coronary stent with the taxus liberte paclitaxel-eluting stent in de novo native coronary artery lesions. *Circulation: Cardiovascular Interventions* 2010;3:556-64.
 37. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and Paclitaxel-Eluting Stent for Coronary Lesions) randomized trial. *Journal of the American College of Cardiology* 2010;56:1187-95.
 38. Serruvs PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. *New England Journal of Medicine*

- 2010;363:136-46.
39. Serruys PW, Garg S, Abizaid A, et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-Month follow-up results of the EXCELLA II study. *EuroIntervention* 2010;6:195-205.
 40. Stone GW, Rizvi A, Newman W, et al. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease. *New England Journal of Medicine* 2010;362:1663-74.
 41. Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *New England Journal of Medicine* 2010;363:943-53.
 42. Amat i Tardiu L, Franco EM, Vicens JML. Contasure-Needleless compared with transobturator-TVT for the treatment of stress urinary incontinence. *International Urogynecology Journal* 2011;22:827-33.
 43. Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. *Journal of the American College of Cardiology* 2011;57:538-45.
 44. Delamarter R, Zigler JE, Balderston RA, et al. Prospective, randomized, multicenter food and drug administration investigational device exemption study of the ProDisc-L total disc replacement compared with circumferential arthrodesis for the treatment of two-level lumbar degenerative disc disease: Results at twenty-four months. *Journal of Bone and Joint Surgery - Series A* 2011;93:705-15.
 45. Elit L, Levine MN, Julian JA, et al. Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia : a randomized trial in Canada and Brazil. *Cancer* 2011;117:1438-45.
 46. Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. *JAMA - Journal of the American Medical Association* 2011;305:569-75.
 47. Klomp M, Beijk MA, Varma C, et al. 1-Year outcome of TRIAS HR (TRI-stent Adjudication Study-High Risk of restenosis): A multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. *JACC: Cardiovascular Interventions* 2011;4:896-904.
 48. Lee CW, Park DW, Seung KB, et al. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. *American Journal of Cardiology* 2011;107:990-4.
 49. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: The Intracoronary stenting and angiographic results: Test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) Trial. *Circulation* 2011;124:624-32.
 50. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *New England Journal of Medicine* 2011;364:1718-27.
 51. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: The excellent (efficacy of Xience/Promus versus cypher to reduce late loss after stenting) randomized trial. *Journal of the American College of Cardiology* 2011;58:1844-54.
 52. Park DW, Kim YH, Song HG, et al. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: A randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-III) trial. *JACC: Cardiovascular Interventions* 2011;4:1096-103.
 53. Pilgrim T, Raber L, Limacher A, et al. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. *Jacc: Cardiovascular Interventions* 2011;4:672-82.
 54. Roos DE, Smith JG, Stephens SW. Radiosurgery versus Surgery, both with Adjuvant Whole Brain Radiotherapy, for Solitary Brain Metastases: A Randomised Controlled Trial. *Clinical Oncology* 2011;23:646-51.
 55. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *New England Journal of Medicine* 2011;364:2187-98.
 56. Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: The PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. *Journal of the American College of Cardiology* 2011;57:1700-8.
 57. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage

- renal cell carcinoma. *European Urology* 2011;59:543-52.
58. Vons C, Barry C, Maitre S, et al. Amoxicillin plus clavulanic acid versus appendectomy for treatment of acute uncomplicated appendicitis: An open-label, non-inferiority, randomised controlled trial. *The Lancet* 2011;377:1573-9.
 59. Worthington-Kirsch RL, Siskin GP, Hegener P, et al. Comparison of the efficacy of the embolic agents acrylamido polyvinyl alcohol microspheres and tris-acryl gelatin microspheres for uterine artery embolization for leiomyomas: A prospective randomized controlled trial. *CardioVascular and Interventional Radiology* 2011;34:493-501.
 60. Xu B, Dou KF, Han YL, et al. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results. *Chinese Medical Journal* 2011;124:811-6.
 61. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: The RESOLUTE US clinical trial. *Journal of the American College of Cardiology* 2011;57:1778-83.
 62. Ahn JM, Park DW, Kim YH, et al. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions a randomized LONG-DES IV trial. *Circulation: Cardiovascular Interventions* 2012;5:633-40.
 63. Bae H, Hatten HP, Jr., Linovitz R, et al. A prospective randomized FDA-IDE trial comparing Cortoss with PMMA for vertebroplasty: a comparative effectiveness research study with 24-month follow-up. *Spine* 2012;37:544-50.
 64. Barber MD, Weidner AC, Sokol AI, et al. Single-incision mini-sling compared with tension-free vaginal tape for the treatment of stress urinary incontinence: A randomized controlled trial. *Obstetrics and Gynecology* 2012;119:328-37.
 65. Carrie D, Berland J, Verheye S, et al. A Multicenter Randomized Trial Comparing Amphilimus- With Paclitaxel-Eluting Stents in De Novo Native Coronary Artery Lesions. *Journal of the American College of Cardiology* 2012.
 66. Fairman RM, Tucheck JM, Lee WA, et al. Pivotal results for the medtronic valiant thoracic stent graft system in the VALOR II trial. *Journal of Vascular Surgery* 2012;56:1222-31.e1.
 67. Fujita J, Kurokawa Y, Sugimoto T, et al. Survival benefit of bursectomy in patients with resectable gastric cancer: interim analysis results of a randomized controlled trial. *Gastric Cancer* 2012;15:42-8.
 68. Gray WA, Yeung AC, Cutlip DE, et al. A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: Final results of the ZoMaxx II trial. *International Journal of Cardiology* 2012;157:96-101.
 69. Grube E, Chevalier B, Guagliumi G, et al. The SPIRIT v Diabetic Study: A randomized clinical evaluation of the XIENCE v everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. *American Heart Journal* 2012;163:867-75.e1.
 70. Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for acute myocardial infarction) trial. *Journal of the American College of Cardiology* 2012;60:381-7.
 71. Jang JW, Lee SS, Song TJ, et al. Endoscopic ultrasound-guided transmural and percutaneous transhepatic gallbladder drainage are comparable for acute cholecystitis. *Gastroenterology* 2012;142:805-11.
 72. Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: The Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). *Circulation* 2012;125:1246-55.
 73. Kadota K, Muramatsu T, Iwabuchi M, et al. Randomized comparison of the nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. *Catheterization and Cardiovascular Interventions* 2012;80:789-96.
 74. Karjalainen PP, Niemela M, Airaksinen JKE, et al. A prospective randomised comparison of titanium-nitride-oxide-coated bioactive stents with everolimus-eluting stents in acute coronary syndrome: The BASE-ACS trial. *EuroIntervention* 2012;8:306-15.
 75. Katsanos K, Karnabatidis D, Kitrou P, et al. Paclitaxel-coated balloon angioplasty vs. plain balloon dilation for the treatment of failing dialysis access: 6-Month interim results from a prospective randomized controlled trial.

- Journal of Endovascular Therapy 2012;19:263-72.
76. Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the randomized evaluation of sirolimus-eluting versus everolimus-eluting stent trial (RESET). *Circulation* 2012;126:1225-36.
 77. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: The bello (balloon elution and late loss optimization) study. *Journal of the American College of Cardiology* 2012;60:2473-80.
 78. Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. *Annals of Oncology* 2012;23:2708-14.
 79. Lukacs B, Loeffler J, Bruyre F, et al. Photoselective vaporization of the prostate with Greenlight 120-W laser compared with monopolar transurethral resection of the prostate: A multicenter randomized controlled trial. *European Urology* 2012;61:1165-73.
 80. Meredith IT, Verheye S, Dubois CL, et al. Primary Endpoint Results of the EVOLVE Trial. A Randomized Evaluation of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent. *Journal of the American College of Cardiology* 2012.
 81. Park HJ, Kim HY, Lee JM, et al. Randomized comparison of the efficacy and safety of zotarolimus-eluting stents vs. sirolimus-eluting stents for percutaneous coronary intervention in chronic total occlusion--CATHolic Total Occlusion Study (CATOS) trial. *Circulation Journal* 2012;76:868-75.
 82. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. *The Lancet* 2012;380:1241-9.
 83. Shadid N, Ceulen R, Nelemans P, et al. Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for the incompetent great saphenous vein. *British Journal of Surgery* 2012;99:1062-70.
 84. von Birgelen C, Basalus MWZ, Tandjung K, et al. A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients. The TWENTE Trial. *Journal of the American College of Cardiology* 2012.
 85. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. *Journal of Clinical Oncology* 2012;30:695-700.
 86. Xu B, Dou K, Yang Y, et al. Nine-month angiographic and 2-year clinical follow-up of the NOYA biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: The NOYA I trial. *EuroIntervention* 2012;8:796-802.
 87. Yang X, Jiang M, Chen X, et al. TVT-O vs. TVT for the treatment of SUI: a non-inferiority study. *International Urogynecology Journal* 2012;23:99-104.
 88. Yang X, Li H. A modified anterior compartment reconstruction and Prolift-a for the treatment of anterior pelvic organ prolapse: a non-inferiority study. *Archives of Gynecology & Obstetrics* 2012;285:1593-7.
 89. Zhang L, Yuan J, Liu G, et al. One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease. *Journal of Interventional Cardiology* 2012;25:604-10.
 90. Bastani H, Drca N, Insulander P, et al. Cryothermal vs. radiofrequency ablation as atrial flutter therapy: a randomized comparison. *Europace* 2013;15:420-8.
 91. Bianchi-Ferraro AMHM, Bella ZIKJD, De ACR, et al. Single-incision sling compared with transobturator sling for treating stress urinary incontinence: A randomized controlled trial. *International Urogynecology Journal* 2013;24:1459-65.
 92. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. *The Lancet* 2013;381:461-7.
 93. Galimberti V, Cole BF, Zurrada S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. *The Lancet Oncology* 2013;14:297-305.
 94. Gao RL, Xu B, Lansky AJ, et al. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: Clinical and angiographic follow-up of the TARGET I trial. *EuroIntervention* 2013;9:75-83.
 95. Hahalis G, Tsigkas G, Xanthopoulou I, et al. Transulnar compared with transradial artery approach as a default strategy for coronary procedures: A randomized trial: The transulnar or transradial instead of coronary transfemoral angiographies study (the AURA of ARTEMIS study).

- Circulation: Cardiovascular Interventions 2013;6:252-61.
96. Haude M, Lee SWL, Worthley SG, et al. The REMEDEE trial: A randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. *JACC: Cardiovascular Interventions* 2013;6:334-43.
 97. Jacobs AK, Normand SLT, Massaro JM, et al. Nonemergency PCI at hospitals with or without on-site cardiac surgery. *New England Journal of Medicine* 2013;368:1498-508.
 98. Liistro F, Porto I, Angioli P, et al. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience v drug-eluting stent in the treatment of de novo coronary stenosis: A randomized trial. *American Heart Journal* 2013;166:920-6.
 99. Moreno R, Garcia E, Teles R, et al. Randomized comparison of sirolimus-eluting and everolimus-eluting coronary stents in the treatment of total coronary occlusions: results from the chronic coronary occlusion treated by everolimus-eluting stent randomized trial. *Circulation: Cardiovascular Interventions* 2013;6:21-8.
 100. Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: A randomized, controlled, noninferiority trial. *Journal of the American College of Cardiology* 2013;62:181-90.
 101. Ribichini F, Romano M, Rosiello R, et al. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease). *JACC Cardiovasc Interv* 2013;6:1012-22.
 102. Rothmund R, Szyrach M, Reda A, et al. A prospective, randomized clinical comparison between UltraCision and the novel sealing and cutting device BiCision in patients with laparoscopic supracervical hysterectomy. *Surgical Endoscopy* 2013;27:3852-9.
 103. Seo JB, Kang SH, Hur SH, et al. Randomized trial comparing the efficacy between different types of paclitaxel-eluting stents: The comparison of Efficacy between COroflex PLEASE and Taxus stent (ECO-PLEASANT) randomized controlled trial. *American Heart Journal* 2013;165:733-43.
 104. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): A randomised, controlled, non-inferiority trial. *The Lancet* 2013;381:651-60.
 105. Sung JY, Baek JH, Kim KS, et al. Single-session treatment of benign cystic thyroid nodules with ethanol versus radiofrequency ablation: a prospective randomized study. *Radiology* 2013;269:293-300.
 106. Tommaselli GA, D'Aferio A, Di Carlo C, et al. Tension-Free Vaginal Tape-O and -Secur for the Treatment of Stress Urinary Incontinence: A Thirty-Six-Month Follow-Up Single-Blind, Double-Arm, Randomized Study. *Journal of Minimally Invasive Gynecology* 2013;20:198-204.
 107. Van Vilsteren FGI, Phoa KN, Alvarez Herrero L, et al. A simplified regimen for focal radiofrequency ablation of Barrett's mucosa: A randomized multicenter trial comparing two ablation regimens. *Gastrointestinal Endoscopy* 2013;78:30-8.
 108. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *New England Journal of Medicine* 2014;370:1790-8.
 109. Aigmuller T, Tammaa A, Tamussino K, et al. Retropubic vs. transobturator tension-free vaginal tape for female stress urinary incontinence: 3-Month results of a randomized controlled trial. *International Urogynecology Journal and Pelvic Floor Dysfunction* 2014;25:1023-30.
 110. Atienza F, Almendral J, Ormaetxe JM, et al. Comparison of radiofrequency catheter ablation of drivers and circumferential pulmonary vein isolation in atrial fibrillation: A noninferiority randomized multicenter RADAR-AF trial. *Journal of the American College of Cardiology* 2014;64:2455-67.
 111. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study. *European Urology* 2014;65:931-42.
 112. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): A multicentre, non-inferiority, randomised controlled trial. *The Lancet Oncology* 2014;15:96-105.
 113. Bikhazi N, Light J, Truitt T, et al. Standalone balloon dilation versus sinus surgery for chronic rhinosinusitis: A prospective, multicenter, randomized, controlled trial with 1-year follow-up. *American Journal of Rhinology and Allergy* 2014;28:323-9.
 114. Chen S, Zhu L, Cai J, et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: A randomized

- noninferiority controlled trial with long-term results at 6 years. *European Urology* 2014;66:284-91.
115. Djehdian LM, Araujo MP, Takano CC, et al. Transobturator sling compared with single-incision mini-sling for the treatment of stress urinary incontinence: A randomized controlled trial. *Obstetrics and Gynecology* 2014;123:553-61.
 116. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. *The Lancet Oncology* 2014;15:1303-10.
 117. Han Y, Xu B, Jing Q, et al. A randomized comparison of novel biodegradable polymer-and durable polymer-coated cobalt-chromium sirolimus-eluting stents. *JACC: Cardiovascular Interventions* 2014;7:1352-60.
 118. Hisey MS, Bae HW, Davis R, et al. Multi-center, prospective, randomized, controlled investigational device exemption clinical trial comparing mobi-C cervical artificial disc to anterior discectomy and fusion in the treatment of symptomatic degenerative disc disease in the cervical spine. *International Journal of Spine Surgery* 2014;8 (no pagination).
 119. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): Survival outcomes of an open-label, non-inferiority, randomised controlled trial. *The Lancet Oncology* 2014;15:767-74.
 120. Kim KB, Hwang HY, Hahn S, et al. A randomized comparison of the Saphenous Vein Versus Right Internal Thoracic Artery as a Y-Composite Graft (SAVE RITA) trial: One-year angiographic results and mid-term clinical outcomes. *Journal of Thoracic & Cardiovascular Surgery* 2014;148:901-7; discussion 7-8.
 121. Lee JY, Park DW, Kim YH, et al. Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus Element) stents in patients with de novo native long coronary artery lesions: A randomized long drug-eluting stent v trial. *Circulation: Cardiovascular Interventions* 2014;7:322-9.
 122. McDougall CG, Johnston SC, Gholkar A, et al. Bioactive versus bare platinum coils in the treatment of intracranial aneurysms: The MAPS (matrix and platinum science) trial. *American Journal of Neuroradiology* 2014;35:935-42.
 123. Minguez JRL, Asensio JMN, Vecino LJD, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (babilon trial): 24-month clinical and angiographic results. *EuroIntervention* 2014;10:50-7.
 124. Nelson PR, Kracjer Z, Kansal N, et al. A multicenter, randomized, controlled trial of totally percutaneous access versus open femoral exposure for endovascular aortic aneurysm repair (the PEVAR trial). *Journal of Vascular Surgery* 2014;59:1181-93.
 125. Park KW, Kang SH, Kang HJ, et al. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based zotarolimus-eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE noninferiority trial. *Journal of the American College of Cardiology* 2014;A. 63:2805-16.
 126. Pilgrim T, Heg D, Roffi M, et al. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): A randomised, single-blind, non-inferiority trial. *The Lancet* 2014;384:2111-22.
 127. Qian J, Zhang YJ, Xu B, et al. Optical coherence tomography assessment of a PLGA-polymer with electro-grafting base layer versus a PLA-polymer sirolimus-eluting stent at three-month follow-up: the BuMA-OCT randomised trial. *EuroIntervention* 2014;10:806-14.
 128. Saito S, Valdes-Chavarri M, Richardt G, et al. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: The CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. *European Heart Journal* 2014;35:2021-31.
 129. Schellart RP, Oude Rengerink K, Van Der Aa F, et al. A randomized comparison of a single-incision midurethral sling and a transobturator midurethral sling in women with stress urinary incontinence: Results of 12-mo follow-up. *European Urology* 2014;66:1179-85.
 130. Tanaka A, Sadahiro S, Suzuki T, et al. Randomized controlled trial comparing subcuticular absorbable suture with conventional interrupted suture for wound closure at elective operation of colon cancer. *Surgery (United States)* 2014;155:486-92.
 131. van den Bos RR, Malskat WS, De Maeseneer MG, et al. Randomized clinical trial of endovenous laser ablation versus steam ablation (LAST trial) for great saphenous varicose veins. *British Journal of Surgery* 2014;101:1077-83.

132. Von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): A randomised, single-blind, multicentre, non-inferiority trial. *The Lancet* 2014;383:413-23.
133. Xu B, Gao R, Wang J, et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: Results from the PEPCAD China ISR trial. *JACC: Cardiovascular Interventions* 2014;7:204-11.
134. Yuan F, Chen X, Song XT, et al. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: Nine-month angiographic and three-year clinical outcomes of hope trial. *Chinese Medical Journal* 2014;127:2561-6.
135. Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-Month results from the IN.PACT deep randomized trial. *Journal of the American College of Cardiology* 2014;64:1568-76.
136. Zhang Q, Qiu JP, Kirtane AJ, et al. Comparison of biodegradable polymer versus durable polymer sirolimus-eluting stenting in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Results of the RESOLVE study. *Journal of Interventional Cardiology* 2014;27:131-41.
137. Abrishamkar S, Kouchakzadeh M, Mirhosseini A, et al. Comparison of open surgical discectomy versus plasma-laser nucleoplasty in patients with single lumbar disc herniation. *Journal of Research in Medical Sciences* 2015;20:1133-7.
138. Banhiran W, Assanasen P, Tantilipikorn P, et al. A randomized study of temperature-controlled versus bipolar radiofrequency for inferior turbinate reduction. *European Archives of Oto-Rhino-Laryngology* 2015;272:2877-84.
139. Baumhauer JF, Singh D, Glazebrook M, et al. Prospective, Randomized, Multi-centered Clinical Trial Assessing Safety and Efficacy of a Synthetic Cartilage Implant Versus First Metatarsophalangeal Arthrodesis in Advanced Hallux Rigidus. *Foot and Ankle International* 2015;37:457-69.
140. Bonjer HJ, Deijen CL, Abis GA, et al. A randomized trial of laparoscopic versus open surgery for rectal cancer. *N Engl J Med* 2015;372:1324-32.
141. Brouwer PA, Brand R, Van Den Akker-Van Marle ME, et al. Percutaneous laser disc decompression versus conventional microdiscectomy in sciatica: A randomized controlled trial. *Spine Journal* 2015;15:857-65.
142. Cooper NAM, Clark TJ, Middleton L, et al. Outpatient versus inpatient uterine polyp treatment for abnormal uterine bleeding: Randomised controlled non-inferiority study. *BMJ (Online)* 2015;350 (no pagination).
143. Detollenaere RJ, den Boon J, Stekelenburg J, et al. Sacrospinous hysteropexy versus vaginal hysterectomy with suspension of the uterosacral ligaments in women with uterine prolapse stage 2 or higher: multicentre randomised non-inferiority trial. *BMJ* 2015;351:h3717.
144. Di Costanzo GG, Tortora R, D'Adamo G, et al. Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: A randomized trial. *Journal of Gastroenterology and Hepatology (Australia)* 2015;30:559-65.
145. Dukkupati SR, Cuoco F, Kutinsky I, et al. Pulmonary Vein Isolation Using the Visually Guided Laser Balloon A Prospective, Multicenter, and Randomized Comparison to Standard Radiofrequency Ablation. *Journal of the American College of Cardiology* 2015;66:1350-60.
146. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. *New England Journal of Medicine* 2015;373:1905-15.
147. Elshal AM, Elkoushy MA, El-Nahas AR, et al. GreenLight™ laser (XPS) photoselective vapo-enucleation versus holmium laser enucleation of the prostate for the treatment of symptomatic benign prostatic hyperplasia: a randomized controlled study. *Journal of urology* 2015;193:927-34.
148. Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes the ACOSOG Z6051 randomized clinical trial. *JAMA - Journal of the American Medical Association* 2015;314:1346-55.
149. Gao R, Yang Y, Han Y, et al. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. *Journal of the American College of Cardiology* 2015;66:2298-309.
150. Garcia R, Yue JJ, Blumenthal S, et al. Lumbar total disc replacement for discogenic low back pain: Two-year outcomes of the activL multicenter randomized controlled IDE clinical trial. *Spine* 2015;40:1873-81.
151. Genereux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. *Journal of the American College of Cardiology* 2015;65:533-43.
152. Gotohda N, Yamanaka T, Saiura A, et al. Impact of energy

- devices during liver parenchymal transection: a multicenter randomized controlled trial. *World Journal of Surgery* 2015;39:1543-9.
153. Hayashi T, Kawakami H, Osanai M, et al. No Benefit of Endoscopic Sphincterotomy Before Biliary Placement of Self-Expandable Metal Stents for Unresectable Pancreatic Cancer. *Clinical Gastroenterology and Hepatology* 2015;13:1151-8.e2.
 154. Hirao M, Kurokawa Y, Fujita J, et al. Long-term outcomes after prophylactic bursectomy in patients with resectable gastric cancer: Final analysis of a multicenter randomized controlled trial. *Surgery (United States)* 2015;157:1099-105.
 155. Kaiser C, Galatius S, Jeger R, et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents : Main results of the Basel Stent Kosten-Effektivitäts Trial-prospective validation examination II (BASKET-PROVE II), A randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2015;131:74-81.
 156. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. *The Lancet* 2015;386:249-57.
 157. Kereiakes DJ, Meredith IT, Windecker S, et al. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial. *Circulation: Cardiovascular Interventions* 2015;8.
 158. Kim JW, Jang JY, Lee CK, et al. Comparison of hemostatic forceps with soft coagulation versus argon plasma coagulation for bleeding peptic ulcer--a randomized trial. *Endoscopy* 2015;47:680-7.
 159. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. *European Heart Journal* 2015;36:3332-42.
 160. Lemos PA, Abizaid AAC, Meireles GC, et al. Metallic Limus-Eluting Stents Abluminally Coated with Biodegradable Polymers: Angiographic and Clinical Comparison of a Novel Ultra-Thin Sirolimus Stent Versus Biolimus Stent in the DESTINY Randomized Trial. *Cardiovascular Therapeutics* 2015;33:367-71.
 161. Luik A, Radzewitz A, Kieser M, et al. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. *Circulation* 2015;132:1311-9.
 162. Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. *New England Journal of Medicine* 2015;372:1204-12.
 163. Patel VV, Whang PG, Haley TR, et al. Superior Interspinous Process Spacer for Intermittent Neurogenic Claudication Secondary to Moderate Lumbar Spinal Stenosis: Two-Year Results from a Randomized Controlled FDA-IDE Pivotal Trial. *Spine* 2015;40:275-82.
 164. Raungaard B, Jensen LO, Tilsted HH, et al. Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): A randomised non-inferiority trial. *The Lancet* 2015;385:1527-35.
 165. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. *New England Journal of Medicine* 2015;373:145-53.
 166. Salminen P, Pajanen H, Rautio T, et al. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: The APPAC randomized clinical trial. *JAMA - Journal of the American Medical Association* 2015;313:2340-8.
 167. Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *European Urology* 2015;68:643-52.
 168. Stevenson ARL, Solomon MJ, Lumley JW, et al. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial. *JAMA - Journal of the American Medical Association* 2015;314:1356-63.
 169. Tutton SM, Pflugmacher R, Davidian M, et al. KAST Study: The kiva system as a vertebral augmentation treatment--A safety and effectiveness trial: A randomized, noninferiority trial comparing the kiva system with balloon kyphoplasty in treatment of osteoporotic vertebral compression fractures. *Spine* 2015;40:865-75.
 170. Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. *New England Journal of Medicine* 2015;373:2038-47.
 171. Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: Results of the randomized BIOFLOW-II trial. *Circulation: Cardiovascular Interventions* 2015;8 (2) (no pagination).

172. Zurakowski A, Buszman PP, Milewski KP, et al. Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for de Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial. *Journal of Interventional Cardiology* 2015;28:348-57.
173. Arnold PM, Sasso RC, Janssen ME, et al. Efficacy of i-factor bone graft versus autograft in anterior cervical discectomy and fusion results of the prospective, randomized, single-blinded food and drug administration investigational device exemption study. *Spine* 2016;41:1075-83.
174. Bisdas T, Borowski M, Stavroulakis K, et al. Endovascular Therapy Versus Bypass Surgery as First-Line Treatment Strategies for Critical Limb Ischemia: Results of the Interim Analysis of the CRITISCH Registry. *JACC: Cardiovascular Interventions* 2016;9:2557-65.
175. Boersma LV, van der Voort P, Debruyne P, et al. Multielectrode Pulmonary Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation: A Multinational Multicenter Randomized Clinical Trial. *Circulation: Arrhythmia and Electrophysiology* 2016;9:e003151.
176. Cote GA, Slivka A, Tarnasky P, et al. Effect of covered metallic stents compared with plastic stents on benign biliary stricture resolution: A randomized clinical trial. *JAMA - Journal of the American Medical Association* 2016;315:1250-7.
177. Delawi D, Jacobs W, Van Susante JLC, et al. OP-1 compared with iliac crest autograft in instrumented posterolateral fusion a randomized, multicenter non-inferiority trial. *Journal of Bone and Joint Surgery - American Volume* 2016;98:441-8.
178. Dreyer K, Lier MCI, Emanuel MH, et al. Hysteroscopic proximal tubal occlusion versus laparoscopic salpingectomy as a treatment for hydrosalpinges prior to IVF or ICSI: An RCT. *Human Reproduction* 2016;31:2005-16.
179. Ishiwatari H, Kawakami H, Hisai H, et al. Balloon catheter versus basket catheter for endoscopic bile duct stone extraction: A multicenter randomized trial. *Endoscopy* 2016;48:350-7.
180. Jensen LO, Thayssen P, Maeng M, et al. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial. *Circulation: Cardiovascular Interventions* 2016;9:07.
181. Kuck KH, Brugada J, Furnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *New England Journal of Medicine* 2016;374:2235-45.
182. Lee TH, Choi JH, Park DH, et al. Similar Efficacies of Endoscopic Ultrasound-guided Transmural and Percutaneous Drainage for Malignant Distal Biliary Obstruction. *Clinical Gastroenterology and Hepatology* 2016;14:1011-9.
183. Lee JH, Kong CB, Yang JJ, et al. Comparison of fusion rate and clinical results between CaO-SiO₂-P₂O₅-B₂O₃ bioactive glass ceramics spacer with titanium cages in posterior lumbar interbody fusion. *Spine Journal: Official Journal of the North American Spine Society* 2016;16:1367-76.
184. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. *New England Journal of Medicine* 2016;374:1609-20.
185. Makikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. *The Lancet* 2016;388:2743-52.
186. Martinkevich P, Rahbek O, Stilling M, et al. Is structural hydroxyapatite tricalcium-phosphate graft or tricortical iliac crest autograft better for calcaneal lengthening osteotomy in childhood? interim results from a randomised, controlled non-inferiority study. *Bone & Joint Journal* 2016;98-B:1554-62.
187. Mehanna H, Wong WL, McConkey CC, et al. PET-CT surveillance versus neck dissection in advanced head and neck cancer. *New England Journal of Medicine* 2016;374:1444-54.
188. Midy D, Papon X, Patra P, et al. Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses. *Annals of Vascular Surgery* 2016;31:99-104.
189. Park SK, Ko BM, Han JP, et al. A prospective randomized comparative study of cold forceps polypectomy by using narrow-band imaging endoscopy versus cold snare polypectomy in patients with diminutive colorectal polyps. *Gastrointestinal Endoscopy* 2016;83:527-32.e1.
190. Pleva L, Kukla P, Kusnierova P, et al. Comparison of the Efficacy of Paclitaxel-Eluting Balloon Catheters and Everolimus-Eluting Stents in the Treatment of Coronary In-Stent Restenosis: The Treatment of In-Stent Restenosis Study. *Circulation: Cardiovascular Interventions*

- 2016;9:e003316.
191. Rosenfield K, Matsumura JS, Chaturvedi S, et al. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. *New England Journal of Medicine* 2016;374:1011-20.
 192. Sabate M, Windecker S, Iniguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. *European Heart Journal* 2016;37:229-40.
 193. Sakamoto Y, Hori S, Oguro S, et al. Delayed Gastric Emptying After Stapled Versus Hand-Sewn Anastomosis of Duodenojejunostomy in Pylorus-Preserving Pancreaticoduodenectomy: a Randomized Controlled trial. *Journal of Gastrointestinal Surgery* 2016;20:595-603.
 194. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. *The Lancet* 2016;388:2479-91.
 195. Stefan V, Ahmed AK, Didier C, et al. Direct implantation of rapamycin-eluting stents with bioresorbable drug carrier technology utilising the svelte coronary stent-on-a-wire: The direct II study. *EuroIntervention* 2016;12:e615-e22.
 196. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting Stents or bypass surgery for left main coronary artery disease. *New England Journal of Medicine* 2016;375:2223-35.
 197. von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. *The Lancet* 2016;388:2607-17.
 198. Witzigmann H, Diener MK, Kissenkotter S, et al. No need for routine drainage after pancreatic head resection: The dual-center, randomized, controlled PANDRA trial (ISRCTN04937707). *Annals of Surgery* 2016;264:528-35.
 199. Xu B, Gao R, Yang Y, et al. Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. *Journal of the American College of Cardiology* 2016;67:2249-58.
 200. Zhang H, Wang X, Deng W, et al. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents Nine months angiographic and 5-year clinical outcomes. *Medicine (United States)* 2016;95 (38) (no pagination).
 201. Ando K, Ishii K, Tada E, et al. Prospective multi-center registry to evaluate efficacy and safety of the newly developed diamond-like carbon-coated cobalt-chromium coronary stent system. *Cardiovascular Intervention and Therapeutics* 2017;32:225-32.
 202. Arezzo A, Passera R, Bullano A, et al. Multi-port versus single-port cholecystectomy: results of a multi-centre, randomised controlled trial (MUSIC trial). *Surgical Endoscopy* 2017;31:2872-80.
 203. Bondi J, Avdagic J, Karlbom U, et al. Randomized clinical trial comparing collagen plug and advancement flap for trans-sphincteric anal fistula. *British Journal of Surgery* 2017;104:1160-6.
 204. Borgstrom A, Nerfeldt P, Friberg D. Adenotonsillotomy versus adenotonsillectomy in pediatric obstructive sleep apnea: An RCT. *Pediatrics* 2017;139 (4) (no pagination).
 205. Chae IH, Yoon CH, Park JJ, et al. Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. *Journal of Korean Medical Science* 2017;32:933-41.
 206. Cho JH, Lee JH, Yeom JS, et al. Efficacy of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in posterolateral lumbar fusion: an open, active-controlled, randomized, multicenter trial. *Spine Journal* 2017;17:1866-74.
 207. Deimling TA, Eldridge JL, Riley KA, et al. Randomized controlled trial comparing operative times between standard and robot-assisted laparoscopic hysterectomy. *International Journal of Gynecology and Obstetrics* 2017;136:64-9.
 208. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. *The Lancet Oncology* 2017;18:336-46.
 209. Fajadet J, Neumann FJ, Hildick-Smith D, et al. Twelve-month results of a prospective, multicentre trial to assess the everolimus-eluting coronary stent system (PROMUS Element): The PLATINUM PLUS all-comers randomised trial. *EuroIntervention* 2017;12:1595-604.
 210. Fernandez-Gonzalez S, Martinez Franco E, Lin Miao X, et al. Contasure-needleless® compared with Monarc® for the treatment of stress urinary incontinence. *International urogynecology journal* 2017;28:1077-84.
 211. Ferrero-De-Loma-Osorio A, Garcia-Fernandez A, Castillo-Castillo J, et al. Time-to-Effect-Based Dosing

- Strategy for Cryoballoon Ablation in Patients with Paroxysmal Atrial Fibrillation: Results of the plusONE Multicenter Randomized Controlled Noninferiority Trial. *Circulation: Arrhythmia and Electrophysiology* 2017;10(12) (no pagination).
212. Franzone A, Zaugg S, Piccolo R, et al. A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. *PLoS ONE* 2017;12(8) (no pagination).
 213. Fujita S, Mizusawa J, Kanemitsu Y, et al. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. *Annals of Surgery* 2017;266:201-7.
 214. Gornet MF, Lanman TH, Burkus JK, et al. Cervical disc arthroplasty with the Prestige LP disc versus anterior cervical discectomy and fusion, at 2 levels: Results of a prospective, multicenter randomized controlled clinical trial at 24 months. *Journal of Neurosurgery: Spine* 2017;26:653-67.
 215. Hahn JY, Choi SH, Jeong JO, et al. Conservative versus aggressive treatment strategy with angiographic guidance alone in patients with intermediate coronary lesions: The SMART-CASE randomized, non-inferiority trial. *International Journal of Cardiology* 2017;240:114-9.
 216. Huddart RA, Birtle A, Maynard L, et al. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. *BJU International* 2017;120:639-50.
 217. Kandzari DE, Smits PC, Love MP, et al. Randomized Comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: Primary Results From the BIONICS Trial (BioNIR Ridaforolimus-Eluting Coronary Stent System in Coronary Stenosis). *Circulation* 2017;136:1304-14.
 218. Kandzari DE, Mauri L, Koolen JJ, et al. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. *The Lancet* 2017;390:1843-52.
 219. Kang SH, Chung WY, Lee JM, et al. Angiographic outcomes of Orsiro biodegradable polymer sirolimus-eluting stents and Resolute Integrity durable polymer zotarolimus-eluting stents: Results of the ORIENT trial. *EuroIntervention* 2017;12:1623-31.
 220. Kitano S, Inomata M, Mizusawa J, et al. Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial. *The Lancet Gastroenterology and Hepatology* 2017;2:261-8.
 221. Lee HJ, Chung MJ, Park JY, et al. A prospective randomized study for efficacy of an uncovered double bare metal stent compared to a single bare metal stent in malignant biliary obstruction. *Surgical Endoscopy* 2017;31:3159-67.
 222. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. *New England Journal of Medicine* 2017;376:1321-31.
 223. Rillig A, Schmidt B, Di Biase L, et al. Manual Versus Robotic Catheter Ablation for the Treatment of Atrial Fibrillation: The Man and Machine Trial. *JACC: Clinical Electrophysiology* 2017;3:875-83.
 224. Rogers JG, Pagani FD, Tatroles AJ, et al. Intrapericardial left ventricular assist device for advanced heart failure. *New England Journal of Medicine* 2017;376:451-60.
 225. Sabadell J, Palau-Gené M, Huguet E, et al. Multicentre randomized trial of the Ajust™ single-incision sling compared to the Align™ transobturator tape sling. *International urogynecology journal* 2017;28:1041-7.
 226. Salehi S, Avall-Lundqvist E, Legerstam B, et al. Robot-assisted laparoscopy versus laparotomy for infrarenal paraaortic lymphadenectomy in women with high-risk endometrial cancer: A randomised controlled trial. *European Journal of Cancer* 2017;79:81-9.
 227. Sano T, Sasako M, Mizusawa J, et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. *Annals of Surgery* 2017;265:277-83.
 228. Savolt A, Peley G, Polgar C, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. *European Journal of Surgical Oncology* 2017;43:672-9.
 229. Shera TA, Choh NA, Gojwari TA, et al. A comparison of imaging guided double percutaneous aspiration injection and surgery in the treatment of cystic echinococcosis of liver. *British Journal of Radiology* 2017;90(1072) (no pagination).
 230. Suh BG, Ahn MW, Kim HJ, et al. Wedge-shaped resection of the posterior bony arch during open door laminoplasty to prevent postoperative motion limitation. *Spine* 2017;42:143-50.

231. Teeuwen K, van der Schaaf RJ, Adriaenssens T, et al. Randomized Multicenter Trial Investigating Angiographic Outcomes of Hybrid Sirolimus-Eluting Stents With Biodegradable Polymer Compared With Everolimus-Eluting Stents With Durable Polymer in Chronic Total Occlusions: The PRISON IV Trial. *JACC: Cardiovascular Interventions* 2017;10:133-43.
232. Tew JM, Strong MJ, Alexanderwest G, et al. A pivotal randomized clinical trial evaluating the safety and effectiveness of a novel hydrogel dural sealant as an adjunct to dural repair. *Operative Neurosurgery* 2017;13:204-12.
233. Worthley SG, Kirtane AJ, Simon DI, et al. First-in-Human Evaluation of a Novel Polymer-Free Drug-Filled Stent: Angiographic, IVUS, OCT, and Clinical Outcomes From the RevElution Study. *JACC: Cardiovascular Interventions* 2017;10:147-56.
234. Abdel-Wahab M, Toelg R, Byrne RA, et al. High-Speed Rotational Atherectomy Versus Modified Balloons Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions. *Circulation: Cardiovascular Interventions* 2018;11:e007415.
235. Abizaid A, Kedev S, Kedhi E, et al. Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. *Eurointervention* 2018;14:e1207-e14.
236. Abt D, Hechelhammer L, Mullhaupt G, et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Randomised, open label, non-inferiority trial. *BMJ (Online)* 2018;361 (no pagination).
237. Baan J, Claessen BE, Dijk KBV, et al. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial. *JACC: Cardiovascular Interventions* 2018;11:275-83.
238. Barbaro NM, Quigg M, Ward MM, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial. *Epilepsia* 2018;59:1198-207.
239. Barendse RM, Musters GD, De Graaf EJR, et al. Randomised controlled trial of transanal endoscopic microsurgery versus endoscopic mucosal resection for large rectal adenomas (TREND Study). *Gut* 2018;67:837-46.
240. Chen YD, Li W, Guan C, et al. Comparison of 2 Different Drug-Coated Balloons in In-Stent Restenosis: The RESTORE ISR China Randomized Trial. *JACC: Cardiovascular Interventions* 2018;11:2368-77.
241. de Goede B, Wijsmuller AR, van Ramshorst GH, et al. Watchful Waiting Versus Surgery of Mildly Symptomatic or Asymptomatic Inguinal Hernia in Men Aged 50 Years and Older: A Randomized Controlled Trial. *Annals of Surgery* 2018;267:42-9.
242. de Winter RJ, Katagiri Y, Asano T, et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. *The Lancet* 2018;391:431-40.
243. Elshal AM, El-Nahas AR, Ghazy M, et al. Low-Power Vs High-Power Holmium Laser Enucleation of the Prostate: Critical Assessment through Randomized Trial. *Urology* 2018;121:58-65.
244. Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of mechanically expanded vs self-expanding transcatheter aortic valve replacement on mortality and major adverse clinical events in high-risk patients with aortic stenosis the REPRISE III randomized clinical trial. *JAMA - Journal of the American Medical Association* 2018;319:27-37.
245. Franzini T, Moura RN, Bonifacio P, et al. Complex biliary stones management: Cholangioscopy versus papillary large balloon dilation - A randomized controlled trial. *Endoscopy International Open* 2018;6:E131-E8.
246. Gilling P, Barber N, Bidair M, et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. *Journal of Urology* 2018;199:1252-61.
247. Gray WA, Soga Y, Prem JT, et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. *The Lancet* 2018;392:1541-51.
248. Guagliumi G, Shimamura K, Sirbu V, et al. Temporal course of vascular healing and neoatherosclerosis after implantation of durable- or biodegradable-polymer drug-eluting stents. *European Heart Journal* 2018;39:2448-56.
249. Han Y, Xu B, Fu G, et al. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents. *JACC: Cardiovascular Interventions* 2018;11:260-72.
250. Hasanov M, Denschlag D, Seemann E, et al. Bipolar vessel-sealing devices in laparoscopic hysterectomies: a multicenter randomized controlled clinical trial. *Archives of Gynecology and Obstetrics* 2018;297:409-14.

251. Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *The Lancet* 2018;392:849-56.
252. Jensen CJ, Richardt G, Tolg R, et al. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: The BIOLUX randomised controlled trial. *EuroIntervention* 2018;14:1096-103.
253. Kawamura T, Takeuchi Y, Asai S, et al. A comparison of the resection rate for cold and hot snare polypectomy for 4-9 mm colorectal polyps: a multicentre randomised controlled trial (CRESCENT study). *Gut* 2018;67:1950-7.
254. Kayama T, Sato S, Sakurada K, et al. Effects of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): A Phase III, noninferiority, randomized controlled trial. *Journal of Clinical Oncology* 2018;36:3282-9.
255. Lansky A, Wijns W, Xu B, et al. Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. *The Lancet* 2018;392:1117-26.
256. Lee TH, Park SH, Yang JK, et al. Is the isolated-tip needle-knife precut as effective as conventional precut fistulotomy in difficult biliary cannulation? *Gut and Liver* 2018;12:597-605.
257. Meyer B, Baranto A, Schils F, et al. Percutaneous interspinous spacer vs decompression in patients with neurogenic claudication: An alternative in selected patients? *Neurosurgery* 2018;82:621-9.
258. Mitchem JB, Stafford C, Francone TD, et al. What is the optimal management of an intra-operative air leak in a colorectal anastomosis? *Colorectal Disease* 2018;20:O39-O45.
259. Mordasini L, Di Bona C, Klein J, et al. 80-W GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Obstruction: 5-Year Outcomes of a Single-center Prospective Randomized Trial. *Urology* 2018;116:144-9.
260. Nakamura M, Otsuji S, Nakagawa Y, et al. Non-inferiority of resolute integrity drug-eluting stent to benchmark Xience drug-eluting stent. *Circulation Journal* 2018;82:2284-91.
261. Nogueira RG, Frei D, Kirmani JF, et al. Safety and efficacy of a 3-dimensional stent retriever with aspiration-based thrombectomy vs aspiration-based thrombectomy alone in acute ischemic stroke intervention a randomized clinical trial. *JAMA Neurology* 2018;75:304-11.
262. Paik WH, Lee TH, Park DH, et al. EUS-Guided Biliary Drainage Versus ERCP for the Primary Palliation of Malignant Biliary Obstruction: A Multicenter Randomized Clinical Trial. *American Journal of Gastroenterology* 2018;113:987-97.
263. Palos CC, Maturana AP, Ghersel FR, et al. Prospective and randomized clinical trial comparing transobturator versus retropubic sling in terms of efficacy and safety. *International Urogynecology Journal* 2018;29:29-35.
264. Panchal R, Denhaese R, Hill C, et al. Anterior and lateral lumbar interbody fusion with supplemental interspinous process fixation: Outcomes from a multicenter, prospective, randomized, controlled study. *International Journal of Spine Surgery* 2018;12:172-84.
265. Papastergiou V, Paraskeva KD, Fragaki M, et al. Cold versus hot endoscopic mucosal resection for nonpedunculated colorectal polyps sized 6-10 mm: A randomized trial. *Endoscopy* 2018;50:403-11.
266. Paradies V, Ben-Yehuda O, Jonas M, et al. A prospective randomised trial comparing the novel ridaforolimus-eluting BioNIR stent to the zotarolimus-eluting Resolute stent: Six-month angiographic and one-year clinical results of the NIREUS trial. *EuroIntervention* 2018;14:86-93.
267. Parekh DJ, Reis IM, Castle EP, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. *The Lancet* 2018;391:2525-36.
268. Pouw RE, Kunzli HT, Bisschops R, et al. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: a multicentre randomised controlled trial. *The Lancet Gastroenterology and Hepatology* 2018;3:566-74.
269. Price MJ, Shlofmitz RA, Spriggs DJ, et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial. *Catheterization and Cardiovascular Interventions* 2018;92:253-9.
270. Ramirez PT, Frumovitz M, Pareja R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. *New England Journal of Medicine* 2018;379:1895-904.
271. Ray AF, Powell J, Speakman MJ, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-

- matched comparison with transurethral resection of the prostate (the UK-ROPE study). *BJU International* 2018;122:270-82.
272. Saito S, Krucoff MW, Nakamura S, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: Primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome. *European Heart Journal* 2018;39:2460-8.
273. Schwaitzberg SD, Roberts K, Romanelli JR, et al. The NOVEL trial: natural orifice versus laparoscopic cholecystectomy-a prospective, randomized evaluation. *Surgical Endoscopy* 2018;32:2505-16.
274. Schwandner T, Thieme A, Scherer R, et al. Randomized clinical trial comparing a small intestinal submucosa anal fistula plug to advancement flap for the repair of complex anal fistulas. *International Journal of Surgery Open* 2018;15:25-31.
275. Stone GW, Ellis SG, Gori T, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. *The Lancet* 2018;392:1530-40.
276. Tang Y, Qiao S, Su X, et al. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. *Jacc: Cardiovascular Interventions* 2018;11:2381-92.
277. Tijssen RYG, Kraak RP, Hofma SH, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. *EuroIntervention* 2018;14:e426-e33.
278. Van De Graaf VA, Noorduyt JCA, Willigenburg NW, et al. Effect of Early Surgery vs Physical Therapy on Knee Function among Patients with Nonobstructive Meniscal Tears: The ESCAPE Randomized Clinical Trial. *JAMA - Journal of the American Medical Association* 2018;320:1328-37.
279. von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial. *The Lancet* 2018;392:1235-45.
280. von Birgelen C, Asano T, Amoroso G, et al. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. *Eurointervention* 2018;13:2026-35.
281. Walsh SJ, Hanratty CG, Watkins S, et al. Culotte stenting for coronary bifurcation lesions with 2nd and 3rd generation everolimus-eluting stents: The CELTIC bifurcation study. *EuroIntervention* 2018;14:e318-e24.
282. Xu K, Han Y, Xu B, et al. Efficacy and safety of a second generation biodegradable polymer sirolimus eluting stent: One year results of the CREDIT 2 trial. *Cardiovascular Therapeutics* 2018;36 (3) (no pagination).
283. Yamaji K, Zanchin T, Zanchin C, et al. Unselected use of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for coronary revascularization. *Circulation: Cardiovascular Interventions* 2018;11 (9) (no pagination).
284. Zou Z, Xu A, Zheng S, et al. Dual-centre randomized-controlled trial comparing transurethral endoscopic enucleation of the prostate using diode laser vs. bipolar plasmakinetic for the treatment of LUTS secondary of benign prostate obstruction: 1-year follow-up results. *World Journal of Urology* 2018;36:1117-26.
285. Balling H. Additional Sacroplasty Does Not Improve Clinical Outcome in Minimally Invasive Navigation-Assisted Screw Fixation Procedures for Nondisplaced Insufficiency Fractures of the Sacrum. *Spine* 2019;44:534-42.
286. Belghazi K, Pouw RE, Koch AD, et al. Self-sizing radiofrequency ablation balloon for eradication of Barrett's esophagus: results of an international multicenter randomized trial comparing 3 different treatment regimens. *Gastrointestinal Endoscopy* 2019;90:415-23.
287. Belghazi K, Scholvinck DW, van Berge Henegouwen MI, et al. Results of a two-phased clinical study evaluating a new multiband mucosectomy device for early Barrett's neoplasia: a randomized pre-esophagectomy trial and a pilot therapeutic pilot study. *Surgical Endoscopy* 2019;33:2864-72.
288. Cremer M, Alfaro K, Garai J, et al. Evaluation of two alternative ablation treatments for cervical pre-cancer against standard gas-based cryotherapy: A randomized non-inferiority study. *International Journal of Gynecological Cancer* 2019;29:851-6.
289. Dua KS, DeWitt JM, Kessler WR, et al. A phase III, multicenter, prospective, single-blinded, noninferiority, randomized controlled trial on the performance of a novel esophageal stent with an antireflux valve (with video).

- Gastrointestinal Endoscopy 2019;90:64-74.e3.
290. Eisenschenk A, Spitzmuller R, Guthoff C, et al. Single versus dual Kirschner wires for closed reduction and intramedullary nailing of displaced fractures of the fifth metacarpal neck (1-2 KiWi): A randomized controlled trial. *Bone and Joint Journal* 2019;101-B:1263-71.
 291. Ghobrial FK, Shoma A, Elshal AM, et al. Randomized Trial Comparing Bipolar Transurethral Vaporization of the Prostate versus GreenLight Laser (XPS-180Watt) Photoselective Vaporization of the Prostate for Treatment of small to moderate Benign Prostatic Obstruction: two-years Outcome. *BJU international* 2019.
 292. Hofmann A, Gorbulev S, Guehring T, et al. Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures: a Prospective, Randomized, Open-Label, Multicenter Study. *Journal of bone and joint surgery American volume* 2019.
 293. Hoogeslag RAG, Brouwer RW, Boer BC, et al. Acute Anterior Cruciate Ligament Rupture: Repair or Reconstruction? Two-Year Results of a Randomized Controlled Clinical Trial. *American Journal of Sports Medicine* 2019;47:567-77.
 294. Jansen MP, Besselink NJ, van Heerwaarden RJ, et al. Knee Joint Distraction Compared with High Tibial Osteotomy and Total Knee Arthroplasty: Two-Year Clinical, Radiographic, and Biochemical Marker Outcomes of Two Randomized Controlled Trials. *Cartilage* 2019.
 295. Kawashima H, Hashimoto S, Ohno E, et al. Comparison of 8- and 10-mm diameter fully covered self-expandable metal stents: A multicenter prospective study in patients with distal malignant biliary obstruction. *Digestive Endoscopy* 2019;31:439-47.
 296. Kenny D, Eicken A, Dahnert I, et al. A randomized, controlled, multi-center trial of the efficacy and safety of the Occlutech Figulla Flex-II Occluder compared to the Amplatzer Septal Occluder for transcatheter closure of secundum atrial septal defects. *Catheterization & Cardiovascular Interventions* 2019;93:316-21.
 297. Kim HH, Han SU, Kim MC, et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. *JAMA Oncology* 2019;5:506-13.
 298. Kinoshita T, Uyama I, Terashima M, et al. Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage II/III Gastric Cancer: a Multicenter Cohort Study in Japan (LOC-A Study). *Annals of surgery* 2019;269:887-94.
 299. Lanz J, Kim WK, Walther T, et al. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. *The Lancet* 2019;394:1619-28.
 300. Li S, Xiao H, Yang L, et al. Electrospun P(LLA-CL) Nanoscale Fibrinogen Patch vs Porcine Small Intestine Submucosa Graft Repair of Inguinal Hernia in Adults: a Randomized, Single-Blind, Controlled, Multicenter, Non-Inferiority Trial. *Journal of the American College of Surgeons* 2019.
 301. Lin HC, He QL, Shao WJ, et al. Partial stapled hemorrhoidopexy versus circumferential stapled hemorrhoidopexy for grade III to IV prolapsing hemorrhoids: A randomized, noninferiority trial. *Diseases of the Colon and Rectum* 2019;62:223-33.
 302. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *New England Journal of Medicine* 2019;380:1695-705.
 303. Maeng M, Christiansen EH, Raungaard B, et al. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial). *JACC: Cardiovascular Interventions* 2019;12:624-33.
 304. Maturana AP, Palos CC, Ghersel FR, et al. Randomized controlled trial comparing mini-sling with transobturator sling for the treatment of stress urinary incontinence. *International Urogynecology Journal* 2019.
 305. Minaga K, Ogura T, Shiomi H, et al. Comparison of the efficacy and safety of endoscopic ultrasound-guided choledochoduodenostomy and hepaticogastrostomy for malignant distal biliary obstruction: Multicenter, randomized, clinical trial. *Digestive Endoscopy* 2019;31:575-82.
 306. Moreu J, Moreno-Gómez R, Pérez de Prado A, et al. First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial. *EuroIntervention* 2019;15:e1081 e9.
 307. Mustapha JA, Brodmann M, Geraghty PJ, et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: Six-month results of the lutonix BTK trial. *Journal of Invasive Cardiology* 2019;31:205-11.

308. Niemeyer P, Laute V, Zinser W, et al. A Prospective, Randomized, Open-Label, Multicenter, Phase III Noninferiority Trial to Compare the Clinical Efficacy of Matrix-Associated Autologous Chondrocyte Implantation With Spheroid Technology Versus Arthroscopic Microfracture for Cartilage Defects of the Knee. *Orthopaedic Journal of Sports Medicine* 2019;7.
309. Noriega D, Marcia S, Theumann N, et al. A prospective, international, randomized, noninferiority study comparing an implantable titanium vertebral augmentation device versus balloon kyphoplasty in the reduction of vertebral compression fractures (SAKOS study). *Spine Journal* 2019;19:1782-95.
310. Popma JJ, Michael Deeb G, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. *New England Journal of Medicine* 2019;380:1706-15.
311. Rissanen TT, Uskela S, Eranen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. *The Lancet* 2019;394:230-9.
312. Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. *The Lancet* 2019;393:1299-309.
313. Rozemeijer R, Stein M, Voskuil M, et al. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent. *Circulation* 2019;139:67-77.
314. Saito S, Toelg R, Witzenbichler B, et al. BIOFLOW-IV, a randomised, intercontinental, multicentre study to assess the safety and effectiveness of the Orsiro sirolimus-eluting stent in the treatment of subjects with de novo coronary artery lesions: primary outcome target vessel failure at 12 months. *Eurointervention* 2019;15:e1006-e13.
315. Seo DW, Sherman S, Dua KS, et al. Covered and uncovered biliary metal stents provide similar relief of biliary obstruction during neoadjuvant therapy in pancreatic cancer: a randomized trial. *Gastrointestinal Endoscopy* 2019;90:602-12.e4.
316. Skoldenberg OG, Rysinska AD, Chammout G, et al. A randomized double-blind noninferiority trial, evaluating migration of a cemented vitamin E-stabilized highly crosslinked component compared with a standard polyethylene component in reverse hybrid total hip arthroplasty. *Bone and Joint Journal* 2019;101-B:1192-8.
317. Smith BC, Crisp CC, Kleeman SD, et al. Uterosacral Ligament Suspension Versus Robotic Sacrocolpopexy for Treatment of Apical Pelvic Organ Prolapse. *Female Pelvic Medicine and Reconstructive Surgery* 2019;25:93-8.
318. Takeuchi Y, Mabe K, Shimodate Y, et al. Continuous anticoagulation and cold snare polypectomy versus heparin bridging and hot snare polypectomy in patients on anticoagulants with subcentimeter polyps. *Annals of Internal Medicine* 2019;171:229-37.
319. Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. *The Lancet* 2019;394:1325-34.
320. Treasure T, Barnard S, Batchelor T, et al. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): A multicentre randomised clinical trial. *Trials* 2019;20 (1) (no pagination).
321. Turk AS, Siddiqui A, Fifi JT, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. *The Lancet* 2019;393:998-1008.
322. Valdes-Chavarri M, Kedev S, Neskovic AN, et al. Randomised evaluation of a novel biodegradable polymer-based sirolimus-eluting stent in ST-segment elevation myocardial infarction: the MASTER study. *Eurointervention* 2019;14:e1836-e42.
323. Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial. *JACC: Cardiovascular Interventions* 2019;12:1691-9.
324. Werner YB, Hakanson B, Martinek J, et al. Endoscopic or surgical myotomy in patients with idiopathic Achalasia. *New England Journal of Medicine* 2019;381:2219-29.
325. Wu Y, Shen L, Yin J, et al. Twelve-month angiographic and clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold and a metallic stent in patients with coronary artery disease. *International Journal of Cardiology* 2019;293:61-6.
326. Yu J, Huang C, Sun Y, et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients with Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association* 2019;321:1983-92.
327. Zaman A, de Winter RJ, Kogame N, et al. Safety and

- efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. *The Lancet* 2019;393:987-97.
328. Beguinot M, Botchorishvili R, Comptour A, et al. Minilaparoscopic Total Hysterectomy in Current Practice Feasibility and Benefits: A Unicentric, Randomized Controlled Trial. *Journal of Minimally Invasive Gynecology* 2020;27:673-80.
329. Bosiers M, Setacci C, De Donato G, et al. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions. *Journal of Endovascular Therapy* 2020;27:287-95.
330. Brown SGA, Ball EL, Perrin K, et al. Conservative versus interventional treatment for spontaneous pneumothorax. *New England Journal of Medicine* 2020;382:405-15.
331. Ganyukov V, Kochergin N, Shilov A, et al. Randomized Clinical Trial of Surgical vs. Percutaneous vs. Hybrid Revascularization in Multivessel Coronary Artery Disease: Residual Myocardial Ischemia and Clinical Outcomes at One Year - Hybrid coronary REvascularization Versus Stenting or Surgery (HREVS). *Journal of Interventional Cardiology* 2020;2020 (no pagination).
332. Insausti I, Saez de Ocariz A, Galbete A, et al. Randomized Comparison of Prostatic Artery Embolization versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia. *Journal of Vascular and Interventional Radiology* 2020.
333. Itkonen Freitas AM, Mentula M, Rahkola-Soisalo P, et al. Tension-Free Vaginal Tape Surgery versus Polyacrylamide Hydrogel Injection for Primary Stress Urinary Incontinence: A Randomized Clinical Trial. *Journal of Urology* 2020;203:372-8.
334. Jensen LO, Maeng M, Raungaard B, et al. Randomised Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent with the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated with Percutaneous Coronary Intervention: The SORT OUT IX Trial. *Circulation* 2020.
335. Katai H, Mizusawa J, Katayama H, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. *The Lancet Gastroenterology and Hepatology* 2020;5:142-51.
336. Khashab MA, Sanaei O, Rivory J, et al. Peroral endoscopic myotomy: anterior versus posterior approach: a randomized single-blinded clinical trial. *Gastrointestinal Endoscopy* 2020;91:288-97.e7.
337. Kissner U, Lill C, Adderson-Kissner C, et al. Total versus subtotal tonsillectomy for recurrent tonsillitis-a prospective randomized noninferiority clinical trial. *Acta Oto Laryngologica* 2020.
338. Leclercq F, Robert P, Akodad M, et al. Prior Balloon Valvuloplasty Versus Direct Transcatheter Aortic Valve Replacement: Results From the DIRECTAVI Trial. *JACC: Cardiovascular Interventions* 2020;13:594-602.
339. Li C, Yang Y, Han Y, et al. Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial. *Clinical Therapeutics* 2020.
340. Menown IBA, Mamas MA, Cotton JM, et al. First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry. *IJC Heart and Vasculature* 2020;26 (no pagination).
341. Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. *European Journal of Cancer* 2020;130:114-25.
342. Park SM, Park J, Jang HS, et al. Biportal endoscopic versus microscopic lumbar decompressive laminectomy in patients with spinal stenosis: a randomized controlled trial. *Spine Journal* 2020;20:156-65.
343. Paul SB, Acharya SK, Gamanagatti SR, et al. Acetic acid versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A randomized controlled trial. *Diagnostic and Interventional Imaging* 2020;101:101-10.
344. Qi S, Yang E, Bao J, et al. Single-Use Versus Reusable Digital Flexible Ureterscopes for the Treatment of Renal Calculi: A Prospective Multicenter Randomized Controlled Trial. *Journal of Endourology* 2020;34:18-24.
345. Reppas L, Arkoudis NA, Spiliopoulos S, et al. Two-Center Prospective Comparison of the Trocar and Seldinger Techniques for Percutaneous Cholecystostomy. *AJR American Journal of Roentgenology* 2020;214:206-12.
346. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. *New England Journal of Medicine* 2020;382:1208-18.
347. Youn YJ, Lee JW, Ahn SG, et al. Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients. *Circ Cardiovasc Interv* 2020;13:e008525.